Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.69 |
| ▸ | MAG | P20916 | 9/20 | 0.66 |
| ▸ | SELP | P16109 | 2/20 | 0.63 |
| ▸ | SELL | P14151 | 1/20 | 0.63 |
| ▸ | SELE | P16581 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12847918 | 1.00 | SIGLEC7 (0.69) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL29432531 | 1.00 | SIGLEC7 (0.69) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL31716740 | 0.98 | SIGLEC7 (0.69) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30450066 | 0.96 | SIGLEC7 (0.66) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL24529621 | 0.96 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL4312517 | 0.96 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL20885234 | 0.96 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL19922285 | 0.96 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL14362211 | 0.96 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL29376404 | 0.96 | SIGLEC7 (0.70) | SIGLEC7MAGSELPSELLSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699158-B | Siglec neutralizing antibodies | 依奈特制药公司 | 2022-06-03 | — | — | CN | claimed |
| CN-111263769-B | SIGLEC-9 neutralizing antibodies | 先天制药公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11623954-B2 | Siglec-9-neutralizing antibodies | INNATE PHARMA (FR) | 2023-04-11 | — | — | US | disclosed |
| US-20230085847-A1 | COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER | INNATE PHARMA (FR) | 2023-03-23 | — | — | US | disclosed |
| US-11447545-B2 | Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer | INNATE PHARMA (FR) | 2022-09-20 | — | — | US | disclosed |
| CN-108699158-B | Siglec neutralizing antibodies | 依奈特制药公司 | 2022-06-03 | — | — | CN | disclosed |